• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Myelofibrosis predicts deep molecular response 4.5 in chronic myeloid leukaemia patients initially treated with imatinib: An extensive, multicenter and retrospective study to develop a prognostic model.

作者信息

Zeng Tian, Yang Xiudi, Wang Yi, Wu Dijiong, Feng Weiying, Lu Ying, Zhu Xiaoqiong, Liu Lirong, Zhou Mei, Zhang Li, Shao Yanping, Qian Honglan, Zhu Feng, Chen Yu, Cao Dan, Huang Li, Feng Xiaoning, Chen Lili, Zhang Gang, Le Jing, Zhu Weiguo, Xia Yongming, Han Yanxia, Jia Yongqing, Tian Guoyan, Zhou Hui, Xu Linjuan, Yin Xiufeng, Tang Qinli, Zhang Yuefeng, Yao Guoli, Lang Xianghua, Zhang Kaifeng, Zhou Xiujie, Guo Junbin, Tu Jinming, Zhao Jianzhi, Wu Gongqiang, Zhang Huiqi, Wu Xiao, Luo Qiulian, Cao Lihong, Chu Binbin, Jiang Wei, Wu Haiying, Huang Liansheng, Hu Meiwei, He Muqing, Zhu Jingjing, Tong Hongyan, Jin Jie, Huang Jian

机构信息

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Zhejiang Clinical Medical Research Center of Hematology, Hangzhou, China.

出版信息

Clin Transl Med. 2024 Nov;14(11):e70101. doi: 10.1002/ctm2.70101.

DOI:10.1002/ctm2.70101
PMID:39576229
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11583811/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b79/11583811/4412bb38c04d/CTM2-14-e70101-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b79/11583811/d5a0d03281ad/CTM2-14-e70101-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b79/11583811/3c12bf41c37b/CTM2-14-e70101-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b79/11583811/4412bb38c04d/CTM2-14-e70101-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b79/11583811/d5a0d03281ad/CTM2-14-e70101-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b79/11583811/3c12bf41c37b/CTM2-14-e70101-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b79/11583811/4412bb38c04d/CTM2-14-e70101-g002.jpg

相似文献

1
Myelofibrosis predicts deep molecular response 4.5 in chronic myeloid leukaemia patients initially treated with imatinib: An extensive, multicenter and retrospective study to develop a prognostic model.骨髓纤维化可预测初始接受伊马替尼治疗的慢性髓性白血病患者的深度分子反应4.5：一项旨在建立预后模型的广泛、多中心回顾性研究。
Clin Transl Med. 2024 Nov;14(11):e70101. doi: 10.1002/ctm2.70101.
2
Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.与伊马替尼相比，第二代BCR-ABL1酪氨酸激酶抑制剂在慢性髓性白血病患者中实现无治疗缓解的治疗价值：一项建模研究
Lancet Haematol. 2019 Aug;6(8):e398-e408. doi: 10.1016/S2352-3026(19)30087-0. Epub 2019 Jun 14.
3
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.酪氨酸激酶抑制剂治疗慢性髓性白血病的停药研究（EURO-SKI）：一项前瞻性、多中心、非随机、试验的预先指定的中期分析。
Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4.
4
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.帕纳替尼与伊马替尼用于新诊断的慢性髓性白血病：一项国际、随机、开放标签、3 期临床试验。
Lancet Oncol. 2016 May;17(5):612-21. doi: 10.1016/S1470-2045(16)00080-2. Epub 2016 Apr 12.
5
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.伊马替尼400mg、伊马替尼800mg、达沙替尼和尼洛替尼用于慢性期慢性髓性白血病患者的长期分子和细胞遗传学反应及生存结果：来自五项临床试验患者数据的回顾性分析
Lancet Haematol. 2015 Mar;2(3):e118-28. doi: 10.1016/S2352-3026(15)00021-6. Epub 2015 Mar 20.
6
Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study.停用伊马替尼治疗达到缓解的可行性：在慢性髓性白血病慢性期研究中使用非专利伊马替尼的试验结果。
Indian J Med Res. 2023 Jan;157(1):87-91. doi: 10.4103/ijmr.ijmr_1090_21.
7
Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study.在持续深度分子缓解的儿童慢性髓性白血病中停用伊马替尼：STOP IMAPED 研究的结果。
Br J Haematol. 2019 May;185(4):718-724. doi: 10.1111/bjh.15826. Epub 2019 Mar 6.
8
Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients.伊马替尼治疗对慢性髓性白血病患者肾性贫血的影响。
J Oncol Pharm Pract. 2023 Dec;29(8):1928-1934. doi: 10.1177/10781552231160113. Epub 2023 Mar 2.
9
Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE).一项关于来那替尼与伊马替尼治疗新诊断的慢性期慢性髓性白血病患者的3期研究（RERISE）的长期数据。
Br J Haematol. 2020 Apr;189(2):303-312. doi: 10.1111/bjh.16381. Epub 2020 Feb 3.
10
Assessment of Imatinib as a Primary Treatment of Chronic Myeloid Leukemia in Chronic Phase: a Cohort Study.
J Oncol Pharm Pract. 2023 Apr;29(3):547-556. doi: 10.1177/10781552221074272. Epub 2022 Jan 20.

本文引用的文献

1
Prognostic Impact of Bone Marrow Fibrosis and Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia.骨髓纤维化的预后影响及酪氨酸激酶抑制剂对慢性髓性白血病骨髓纤维化的影响。
Clin Lymphoma Myeloma Leuk. 2024 Apr;24(4):e161-e167. doi: 10.1016/j.clml.2023.12.015. Epub 2024 Jan 17.
2
Perspectives on validation of clinical predictive algorithms.临床预测算法的验证视角。
NPJ Digit Med. 2023 May 6;6(1):86. doi: 10.1038/s41746-023-00832-9.
3
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.
慢性期慢性髓性白血病治疗的临床医生视角。
J Hematol Oncol. 2022 Jul 11;15(1):90. doi: 10.1186/s13045-022-01309-0.
4
Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?为什么在慢性髓性白血病中实现深度分子反应至关重要？
Haematologica. 2020 Dec 1;105(12):2730-2737. doi: 10.3324/haematol.2019.240739.
5
Molecular monitoring in CML: how deep? How often? How should it influence therapy?CML 中的分子监测：多深？多频繁？它应如何影响治疗？
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):168-176. doi: 10.1182/asheducation-2018.1.168.
6
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
7
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.早期分子反应和女性性别强烈预测慢性髓细胞白血病患者伊马替尼停药的标准，即 BCR-ABL1 持续不可检测。
Blood. 2013 May 9;121(19):3818-24. doi: 10.1182/blood-2012-10-462291. Epub 2013 Mar 20.
8
Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia.
Leukemia. 2007 Dec;21(12):2420-7. doi: 10.1038/sj.leu.2404917. Epub 2007 Sep 6.
9
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial.
Leukemia. 2003 Dec;17(12):2444-53. doi: 10.1038/sj.leu.2403172.